Document is current
Any future updates will be listed below
-
Authors
Khan, Zia http://orcid.org/0000-0002-7859-3489
Hammer, Christian
Carroll, Jonathan
Di Nucci, Flavia
Acosta, Sergio Ley
Maiya, Vidya
Bhangale, Tushar
Hunkapiller, Julie
Mellman, Ira
Albert, Matthew L. http://orcid.org/0000-0001-7285-6973
McCarthy, Mark I. http://orcid.org/0000-0002-4393-0510
Chandler, G. Scott http://orcid.org/0000-0001-5339-9906
- License Information
-
More Information
Article History
Received: 29 October 2020
Accepted: 5 May 2021
First Online: 7 June 2021
Competing interests
: All authors are current or former employees of Genentech/Roche. M.L.A. is currently an employee of insitro. Z.K. and G.S.C. are co-inventors on a patent application using the methods described here to identify patients treated with immune checkpoint inhibitors at high risk for endocrine irAE and selection of TNBC patients that might benefit from PD-1 checkpoint inhibitor treatment.
